All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 69 points (0.4%) at 16,709 as of Monday, Feb. 29, 2016, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,159 issues advancing vs. 752 declining with 167 unchanged.

The Drugs industry currently is unchanged today versus the S&P 500, which is up 0.5%. Top gainers within the industry include

Ionis Pharmaceuticals

(

IONS

), up 6.8%, and

Alexion Pharmaceuticals

(

ALXN

), up 1.0%. On the negative front, top decliners within the industry include

Endo International

(

ENDP

), down 18.1%,

Horizon Pharma

(

HZNP

), down 17.0%,

Mallinckrodt

(

MNK

), down 4.8%,

AstraZeneca

(

AZN

), down 1.9% and

Shire

(

SHPG

), down 1.8%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Abbott Laboratories

(

ABT

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Abbott Laboratories is up $0.30 (0.8%) to $39.82 on light volume. Thus far, 1.7 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 7.3 million shares. The stock has ranged in price between $39.28-$39.82 after having opened the day at $39.45 as compared to the previous trading day's close of $39.52.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Abbott Laboratories manufactures and sells health care products worldwide. Abbott Laboratories has a market cap of $58.4 billion and is part of the health care sector. Shares are down 12.0% year-to-date as of the close of trading on Friday. Currently there are 12 analysts who rate Abbott Laboratories a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Abbott Laboratories

as a

buy

. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and notable return on equity. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Abbott Laboratories Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Bristol-Myers Squibb Company

(

BMY

) is up $0.44 (0.7%) to $62.69 on light volume. Thus far, 1.6 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 6.9 million shares. The stock has ranged in price between $61.99-$62.73 after having opened the day at $62.25 as compared to the previous trading day's close of $62.25.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $105.2 billion and is part of the health care sector. Shares are down 9.5% year-to-date as of the close of trading on Friday. Currently there are 7 analysts who rate Bristol-Myers Squibb Company a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates

Bristol-Myers Squibb Company

as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full

Bristol-Myers Squibb Company Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Gilead

(

GILD

) is up $0.78 (0.9%) to $88.88 on light volume. Thus far, 3.9 million shares of Gilead exchanged hands as compared to its average daily volume of 12.0 million shares. The stock has ranged in price between $87.85-$88.91 after having opened the day at $87.87 as compared to the previous trading day's close of $88.10.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $123.2 billion and is part of the health care sector. Shares are down 12.9% year-to-date as of the close of trading on Friday. Currently there are 12 analysts who rate Gilead a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Gilead

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, attractive valuation levels, impressive record of earnings per share growth and compelling growth in net income. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Gilead Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).